Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings advances medical cannabis supply chain strategy

The aim is to develop final dose form medicines for the treatment of chronic pain.
Cannabis plants
A maximum of 435 plants are being planted at a facility near Santiago

AusCann Group Holdings Ltd’s (ASX:AC8) Chilean joint venture DayaCann is planting its second medicinal cannabis crop in Chile.

This follows the grant of a cultivation licence for the crop in November by Chilean authorities.

Up to 435 plants are being planted at DayaCann’s 30-hectare facility south of Santiago.

The crop is expected to be harvested in the first half of 2018 and will provide a range of cannabis strains to be extracted.

READ: AusCann Group Holdings secures medical cannabis cultivation licence

Elaine Darby, managing director, said: “The harvest of our first crop in Chile in April this year saw AusCann yield over 400 kilograms of dried cannabis product.

“We have since selected the highest yielding strains from that crop and are now cultivating our second crop using these strains.

“From these strains, it is our intention to develop final dose form medicines for the treatment of chronic and neuropathic pain that will be supplied into the significant Latin American market.”

Strains will be processed into trial formulations

After extraction the cannabis strains will be processed into trial cannabinoid formulations.

The product can then progress to clinical trials and registration with the Chilean National Institute of Public Health.

After registration, Chilean legislation permits the export of medications.

AusCann and the DayaCann joint venture are focused on establishing a fully integrated supply chain in Latin America.

This will see the joint venture manage operations from cultivation through to the development and sale of final dose form medications.

Chile operations complement Australian partnership

The Chilean operations complement the Australian strategic partnership between AusCann and Tasmanian Alkaloids with fully integrated cultivation and manufacturing of final dose form medications.

READ: AusCann Group Holdings shares pop on grant of new medical cannabis licence

The AusCann and Tasmanian Alkaloids partnership is the only group to hold all necessary licences to produce final dose form Australian cannabinoid medications.

AusCann is the only listed company that is integrated across the full spectrum of the Australian medicinal cannabis supply chain.

In the immediate term AusCann will source and supply cannabinoid medicines to Australian patients from its Canadian strategic partner Canopy Growth.

AusCann manufacturing is also well positioned to supply Australian patients and future export potential.

READ: AusCann Group Holdings welcomes medical cannabis legislation

The company is well funded with cash of $13.7 million at the end of the September quarter of 2017 and a market cap of $88 million.

It is on track with licensing to commence Australian cultivation and manufacturing cannabinoid products in 2018.

Milestones for 2018

AusCann's key milestones for 2018:

- Importation of medications from Canopy Growth to meet immediate demand and initial revenue generation;
- Growth in prescriptions by authorised prescribers;
- Establishment of manufacturing capabilities in Chile;
- Commence commercial cultivation activities in Tasmania;
- Commence R&D genetics program for the development of high yielding cannabis strains; and
- First harvest and products manufactured at Tasmanian facility.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use